SCHEMBL5227864

SCHEMBL5227864

COc1ccc2ncc(F)c([C@H](O)CCC3CCN(CCSc4cccs4)CC3C(=O)O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 12/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226209 1.00 KCNH2 (1.00) KCNH2
SCHEMBL29691634 1.00 KCNH2 (1.00) KCNH2
Hydrochloric Acid SCHEMBL6806087 0.99 KCNH2 (0.99) KCNH2
Hydrochloric Acid SCHEMBL6806090 0.99 KCNH2 (0.99) KCNH2
SCHEMBL3252977 0.95 KCNH2 (0.91) KCNH2
SCHEMBL3252971 0.95 KCNH2 (0.91) KCNH2
SCHEMBL6805965 0.93 KCNH2 (0.87) KCNH2
SCHEMBL6805962 0.93 KCNH2 (0.87) KCNH2
SCHEMBL6805960 0.93 KCNH2 (0.87) KCNH2
SCHEMBL6798610 0.93 KCNH2 (0.86) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370550-B1 QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME NOVEXEL (FR) 2007-05-23 EP disclosed
US-6815547-B2 ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS AVENTIS PHARMA S.A. (FR) 2004-11-09 US disclosed
EP-1370550-A1 QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2003-12-17 EP disclosed
US-20030171369-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them AVENTIS PHARMA S.A. 2003-09-11 US disclosed
US-6602884-B2 Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella AVENTIS PHARMA S.A. (FR) 2003-08-05 US disclosed
US-20020177606-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them NOVEXEL (FR) 2002-11-28 US disclosed
WO-2002072572-A1 QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177606-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them QDPR, MRPL21, RPLP2 KCNH2 656/4885
US-20030171369-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them QDPR, MRPL21, RPLP2 KCNH2 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.